SKYE

$0.65-0.01 (-0.95%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.65
Potential Upside
5%
Whystock Fair Value$0.68
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peri...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$20.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-36.86%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.77

Recent News

MarketBeat
Mar 18, 2026

Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference

Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 12, 2026

Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...

Skye Bioscience Inc (SKYE) reports promising weight loss results and strategic R&D collaborations, despite challenges in dosing and delivery.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Jan 12, 2026

Companies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Jan 7, 2026

A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience

Halozyme Therapeutics (HALO) shares are in focus after the company entered a non exclusive global collaboration with Skye Bioscience in December 2025 to apply its ENHANZE drug delivery technology to a potential obesity treatment. See our latest analysis for Halozyme Therapeutics. The Skye Bioscience agreement lands at a time when Halozyme’s share price has picked up momentum, with a 15.47% 1 month share price return and 12.16% 3 month share price return. The 1 year total shareholder return of...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 11, 2025

Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ...

Skye Bioscience Inc (SKYE) reports encouraging phase 2A study outcomes but faces increased R&D expenses and net loss.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.